1
|
Stefani C, Bruchez AM, Rosasco MG, Yoshida AE, Fasano KJ, Levan PF, Lorant A, Hubbard NW, Oberst A, Stuart LM, Lacy-Hulbert A. LITAF protects against pore-forming protein-induced cell death by promoting membrane repair. Sci Immunol 2024; 9:eabq6541. [PMID: 38181093 DOI: 10.1126/sciimmunol.abq6541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 11/09/2023] [Indexed: 01/07/2024]
Abstract
Pore-forming toxins (PFTs) are the largest class of bacterial toxins and contribute to virulence by triggering host cell death. Vertebrates also express endogenous pore-forming proteins that induce cell death as part of host defense. To mitigate damage and promote survival, cells mobilize membrane repair mechanisms to neutralize and counteract pores, but how these pathways are activated is poorly understood. Here, we use a transposon-based gene activation screen to discover pathways that counteract the cytotoxicity of the archetypal PFT Staphylococcus aureus α-toxin. We identify the endolysosomal protein LITAF as a mediator of cellular resistance to PFT-induced cell death that is active against both bacterial toxins and the endogenous pore, gasdermin D, a terminal effector of pyroptosis. Activation of the ubiquitin ligase NEDD4 by potassium efflux mobilizes LITAF to recruit the endosomal sorting complexes required for transport (ESCRT) machinery to repair damaged membrane. Cells lacking LITAF, or carrying naturally occurring disease-associated mutations of LITAF, are highly susceptible to pore-induced death. Notably, LITAF-mediated repair occurs at endosomal membranes, resulting in expulsion of damaged membranes as exosomes, rather than through direct excision of pores from the surface plasma membrane. These results identify LITAF as a key effector that links sensing of cellular damage to repair.
Collapse
Affiliation(s)
- Caroline Stefani
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
| | - Anna M Bruchez
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
| | - Mario G Rosasco
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
| | - Anna E Yoshida
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
| | - Kayla J Fasano
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Paula F Levan
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
| | - Alina Lorant
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
- Department of Immunology, University of Washington, Seattle, WA, USA
| | | | - Andrew Oberst
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Lynda M Stuart
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
- Institute for Protein Design, Department of Biochemistry, University of Washington, Seattle, WA, USA
| | - Adam Lacy-Hulbert
- Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
- Department of Immunology, University of Washington, Seattle, WA, USA
| |
Collapse
|
2
|
Hubbard NW, Ames JM, Maurano M, Chu LH, Somfleth KY, Gokhale NS, Werner M, Snyder JM, Lichauco K, Savan R, Stetson DB, Oberst A. ADAR1 mutation causes ZBP1-dependent immunopathology. Nature 2022; 607:769-775. [PMID: 35859177 PMCID: PMC9339495 DOI: 10.1038/s41586-022-04896-7] [Citation(s) in RCA: 76] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 05/23/2022] [Indexed: 01/22/2023]
Abstract
The RNA-editing enzyme ADAR1 is essential for the suppression of innate immune activation and pathology caused by aberrant recognition of self-RNA, a role it carries out by disrupting the duplex structure of endogenous double-stranded RNA species1,2. A point mutation in the sequence encoding the Z-DNA-binding domain (ZBD) of ADAR1 is associated with severe autoinflammatory disease3-5. ZBP1 is the only other ZBD-containing mammalian protein6, and its activation can trigger both cell death and transcriptional responses through the kinases RIPK1 and RIPK3, and the protease caspase 8 (refs. 7-9). Here we show that the pathology caused by alteration of the ZBD of ADAR1 is driven by activation of ZBP1. We found that ablation of ZBP1 fully rescued the overt pathology caused by ADAR1 alteration, without fully reversing the underlying inflammatory program caused by this alteration. Whereas loss of RIPK3 partially phenocopied the protective effects of ZBP1 ablation, combined deletion of caspase 8 and RIPK3, or of caspase 8 and MLKL, unexpectedly exacerbated the pathogenic effects of ADAR1 alteration. These findings indicate that ADAR1 is a negative regulator of sterile ZBP1 activation, and that ZBP1-dependent signalling underlies the autoinflammatory pathology caused by alteration of ADAR1.
Collapse
Affiliation(s)
| | - Joshua M Ames
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Megan Maurano
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Lan H Chu
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Kim Y Somfleth
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Nandan S Gokhale
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Margo Werner
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Jessica M Snyder
- Department of Comparative Medicine, University of Washington, Seattle, WA, USA
| | - Katrina Lichauco
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Ram Savan
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Daniel B Stetson
- Department of Immunology, University of Washington, Seattle, WA, USA
| | - Andrew Oberst
- Department of Immunology, University of Washington, Seattle, WA, USA.
| |
Collapse
|
3
|
Weliwitigoda A, Palle P, Gessner M, Hubbard NW, Oukka M, Bettelli E. Cutting Edge: DOCK8 Regulates a Subset of Dendritic Cells That Is Critical for the Development of Experimental Autoimmune Encephalomyelitis. J Immunol 2021; 207:2417-2422. [PMID: 34663621 DOI: 10.4049/jimmunol.2001294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 09/22/2021] [Indexed: 01/03/2023]
Abstract
Dedicator of cytokinesis 8 (DOCK8) is a guanine nucleotide exchange factor with an essential role in cytoskeletal rearrangement, cell migration, and survival of various immune cells. Interestingly, DOCK8-deficient mice are resistant to the development of experimental autoimmune encephalomyelitis (EAE). To understand if EAE resistance in these mice results from an alteration in dendritic cell (DC) functions, we generated mice with conditional deletion of DOCK8 in DCs and observed attenuated EAE in these mice compared with control mice. Additionally, we demonstrated that DOCK8 is important for the existence of splenic conventional DC2 and lymph node migratory DCs and further established that migratory DC, rather than resident DC, are essential for the generation and proliferation of pathogenic T cell populations upon immunization with myelin Ag in adjuvant. Therefore, our data suggest that limiting migratory DCs through DOCK8 deletion and possibly other mechanisms could limit the development of CNS autoimmunity.
Collapse
Affiliation(s)
- Asanga Weliwitigoda
- Immunology Program, Benaroya Research Institute, Seattle, WA; and.,Department of Immunology, University of Washington, Seattle, WA
| | - Pushpalatha Palle
- Immunology Program, Benaroya Research Institute, Seattle, WA; and.,Department of Immunology, University of Washington, Seattle, WA
| | - Melissa Gessner
- Immunology Program, Benaroya Research Institute, Seattle, WA; and.,Department of Immunology, University of Washington, Seattle, WA
| | | | - Mohamed Oukka
- Department of Immunology, University of Washington, Seattle, WA
| | - Estelle Bettelli
- Immunology Program, Benaroya Research Institute, Seattle, WA; and .,Department of Immunology, University of Washington, Seattle, WA
| |
Collapse
|
4
|
Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, Chiang K, Daniels BP, Baker D, Oberst A. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol 2020; 4:4/36/eaaw2004. [PMID: 31227597 DOI: 10.1126/sciimmunol.aaw2004] [Citation(s) in RCA: 211] [Impact Index Per Article: 52.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 04/24/2019] [Indexed: 12/13/2022]
Abstract
Although the signaling events that induce different forms of programmed cell death are well defined, the subsequent immune responses to dying cells in the context of cancer remain relatively unexplored. Necroptosis occurs downstream of the receptor-interacting protein kinases RIPK1 and RIPK3, whose activation leads to lytic cell death accompanied by de novo production of proinflammatory mediators. Here, we show that ectopic introduction of necroptotic cells to the tumor microenvironment promotes BATF3+ cDC1- and CD8+ leukocyte-dependent antitumor immunity accompanied by increased tumor antigen loading by tumor-associated antigen-presenting cells. Furthermore, we report the development of constitutively active forms of the necroptosis-inducing enzyme RIPK3 and show that delivery of a gene encoding this enzyme to tumor cells using adeno-associated viruses induces tumor cell necroptosis, which synergizes with immune checkpoint blockade to promote durable tumor clearance. These findings support a role for RIPK1/RIPK3 activation as a beneficial proximal target in the initiation of tumor immunity. Considering that successful tumor immunotherapy regimens will require the rational application of multiple treatment modalities, we propose that maximizing the immunogenicity of dying cells within the tumor microenvironment through specific activation of the necroptotic pathway represents a beneficial treatment approach that may warrant further clinical development.
Collapse
Affiliation(s)
- Annelise G Snyder
- Department of Immunology, University of Washington, Seattle, WA 98109, USA
| | - Nicholas W Hubbard
- Department of Immunology, University of Washington, Seattle, WA 98109, USA
| | - Michelle N Messmer
- Department of Immunology, University of Washington, Seattle, WA 98109, USA
| | - Sigal B Kofman
- Department of Immunology, University of Washington, Seattle, WA 98109, USA
| | - Cassidy E Hagan
- Department of Immunology, University of Washington, Seattle, WA 98109, USA
| | - Susana L Orozco
- Department of Immunology, University of Washington, Seattle, WA 98109, USA.,Molecular and Cellular Biology Program, University of Washington, Seattle, WA 98109, USA
| | - Kristy Chiang
- Molecular and Cellular Biology Program, University of Washington, Seattle, WA 98109, USA
| | - Brian P Daniels
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ 08854, USA
| | - David Baker
- Institute for Protein Design, University of Washington, Seattle, WA 98109, USA
| | - Andrew Oberst
- Department of Immunology, University of Washington, Seattle, WA 98109, USA.
| |
Collapse
|
5
|
Humbert O, Chan F, Rajawat YS, Torgerson TR, Burtner CR, Hubbard NW, Humphrys D, Norgaard ZK, O'Donnell P, Adair JE, Trobridge GD, Scharenberg AM, Felsburg PJ, Rawlings DJ, Kiem HP. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy. Blood Adv 2018; 2:987-999. [PMID: 29720491 PMCID: PMC5942001 DOI: 10.1182/bloodadvances.2018016451] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Accepted: 03/25/2018] [Indexed: 11/20/2022] Open
Abstract
Hematopoietic stem-cell gene therapy is a promising treatment of X-linked severe combined immunodeficiency disease (SCID-X1), but currently, it requires recipient conditioning, extensive cell manipulation, and sophisticated facilities. With these limitations in mind, we explored a simpler therapeutic approach to SCID-X1 treatment by direct IV administration of foamy virus (FV) vectors in the canine model. FV vectors were used because they have a favorable integration site profile and are resistant to serum inactivation. Here, we show improved efficacy of our in vivo gene therapy platform by mobilization with granulocyte colony-stimulating factor (G-CSF) and AMD3100 before injection of an optimized FV vector incorporating the human phosphoglycerate kinase enhancerless promoter. G-CSF/AMD3100 mobilization before FV vector delivery accelerated kinetics of CD3+ lymphocyte recovery, promoted thymopoiesis, and increased immune clonal diversity. Gene-corrected T lymphocytes exhibited a normal CD4:CD8 ratio and a broad T-cell receptor repertoire and showed restored γC-dependent signaling function. Treated animals showed normal primary and secondary antibody responses to bacteriophage immunization and evidence for immunoglobulin class switching. These results demonstrate safety and efficacy of an accessible, portable, and translatable platform with no conditioning regimen for the treatment of SCID-X1 and other genetic diseases.
Collapse
Affiliation(s)
- Olivier Humbert
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Frieda Chan
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Yogendra S Rajawat
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Troy R Torgerson
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
- Department of Pediatrics and
| | - Christopher R Burtner
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Nicholas W Hubbard
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
- Department of Immunology, University of Washington, Seattle, WA
| | - Daniel Humphrys
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Zachary K Norgaard
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Patricia O'Donnell
- Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - Jennifer E Adair
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
- Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Grant D Trobridge
- Department of Pharmaceutical Sciences, Washington State University, Pullman, WA; and
| | - Andrew M Scharenberg
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
- Department of Pediatrics and
- Department of Immunology, University of Washington, Seattle, WA
| | - Peter J Felsburg
- Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
| | - David J Rawlings
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
- Department of Pediatrics and
- Department of Immunology, University of Washington, Seattle, WA
| | - Hans-Peter Kiem
- Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA
- Department of Medicine, University of Washington School of Medicine, Seattle, WA
- Department of Pathology, University of Washington School of Medicine, Seattle, WA
| |
Collapse
|
6
|
Hubbard NW, Hagin D, Sommer KM, Song Y, Khan I, Scharenberg AM, Rawlings DJ, Torgerson TR. 40. Nuclease-Targeted Gene-Editing of FOXP3 in Primary T Cells Creates a Stable and Functional T reg Phenotype. Mol Ther 2016. [DOI: 10.1016/s1525-0016(16)32849-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|